

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 April 2013 (18.04.2013)



(10) International Publication Number
WO 2013/054331 A8

(51) International Patent Classification:

C07K 16/28 (2006.01) *G01N 33/53* (2006.01)
C07K 16/30 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/IL2012/050402

(22) International Filing Date:

10 October 2012 (10.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/IL2011/000808

11 October 2011 (11.10.2011)

IL

(71) Applicants: **TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.** [IL/IL]; The Chaim Sheba Medical Center Tel Hashomer, 52621 Ramat Gan (IL). **CCAM BIOTHERAPEUTICS LTD.** [IL/IL]; Tel-Hai Industrial Park, P.O. Box 408, 11013 Kiryat-Shmona (IL). **RAMOT AT TEL-**

AVIV UNIVERSITY LTD. [IL/IL]; P.O. Box 39296, 6139201 Tel-Aviv (IL).

(72) Inventors: **MARKEL, Gal**; 50/6 Bnei Dan Street, 62264 Tel Aviv (IL). **BEN MOSHE, Tehila**; Koranit, 20181 Misgav (IL). **SAPIR, Yair**; Hadekel 16, 42860 Burgata (IL). **MANDEL, Ilana**; Hate'ena 3, 29066 Kiryat Yam (IL). **SCHACHTER, Jacob**; 258 Derech Ben Gurion, 53326 Givatayim (IL). **ORTENBERG, Rona**; 14 Recanati Street, Apartment 50, 69494 Tel-Aviv (IL).


(74) Agents: **WEBB & CO** et al.; P.O. Box 2189, 76121 Rehovot (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,

[Continued on next page]

(54) Title: ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE (CEACAM)

Figure 9



(57) Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.



RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
— with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))
— with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

10 April 2014

(15) Information about Correction:

see Notice of 10 April 2014